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Key points 
In Norway there have been large and persistent inter-county variations in sales of lipid-lowering 
drugs (LLDs). 
 Inter-county differences in LLD sales are not explained by cardiovascular morbidity, 
age distribution, socioeconomic structure, or access to health care services. 
 Variation in threshold and intensity of LLDs for primary prevention are contributing 
factors to regional differences in LLD sales. 
 Feasible intervention thresholds for primary prevention with concurrent reimbursement 
rules, should be defined in guidelines to avoid unintentional variation in LLD use in the 
future.  
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Abstract  
Objective 
To study and compare plausible factors that might explain varying sales of lipid-lowering drugs 
(LLDs) in the two neighbouring counties Hedmark and Oppland in Norway, with a similar age 
distribution, socioeconomic structure, and access to health care services. 
Design, setting, subjects 
Cross-sectional population study comprising 10 598 attendants aged 40, 45, 60 and 75 years in 
the OPPHED Health Study, 2000-2001 (attendance rate 61%).  
Main outcome measure 
Treatment eligibility (cardiovascular morbidity and risk-score), treatment frequency in 
treatment-eligible subgroups and treatment intensity in terms of achievement of total 
cholesterol (TC) goal. 
Main results 
Proportions eligible for LLD treatment in Hedmark and Oppland were similar. There was no 
difference in prevalence of LLD use among participants with cardiovascular disease or diabetes 
(secondary prevention subgroup). However, LLD use among men in the primary prevention 
subgroup was higher in Hedmark compared with Oppland, 6.3% and 4.1%, respectively 
(p<0.05). The same tendency was seen among women. In both sexes, more LLD users in the 
primary prevention subgroup achieved the TC goal in Hedmark compared with Oppland 
(p<0.05).  
Conclusion and implications 
The proportion of the population eligible for LLD treatment in the two counties should imply 
similar treatment rates in both. Higher LLD treatment frequency and intensity in the primary 
prevention subgroup in Hedmark are probably both contributing factors that explain the higher 
sales of LLDs in Hedmark compared with Oppland. Feasible intervention thresholds for 
primary prevention with concurrent reimbursement rules, should be defined in guidelines to 
avoid unintentional variation in LLD use in the future.  
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Introduction 
The 2003 European guidelines on cardiovascular disease (CVD) prevention have provoked a 
debate regarding their estimated impact on clinical practice relating to risk labelling, 
medicalisation, as well resource allocation within the health care system [1-4]. However, 
whereas implementation of the guidelines could imply a larger part of the population on 
cardiovascular preventive therapy in the future [5, 6], variation in lipid-lowering drug (LLD) 
sales across Scandinavia and the rest of Europe may reflect uncertainty about how to manage 
existing guidelines in clinical practice [7].  The variations in LLD use between countries have 
been little investigated, but may be explained by differences in national treatment guidelines 
and drug reimbursement systems, as well as variations in cardiovascular morbidity [8, 9].  
The sales of LLDs have increased remarkably in Norway since 1994, and are high compared to 
other European countries [7, 10, 11]. However, within Norway the inter-county variations in 
LLD sales have been large and persistent (Figure 1) [11]. In 2000–2001 the sales of LLDs were 
about 40% higher in Hedmark compared to Oppland. The two neighbouring counties have 
similar age distribution, rural-urban distribution, socioeconomic structures and access to health 
care services, and these factors may be excluded as major factors contributing to variations in 
LLD sales [12]. 
The size of the population eligible for LLD treatment is defined by guidelines, which are 
subject to changes over time [1, 13-16]. The proportion treated are influenced by 
reimbursement regulations, which also may vary over time [17-19]. Furthermore, the 
prevalence of LLD use depends on the extent to which treatment-eligible individuals are treated 
in clinical practice. There is documented a gap between guidelines for cholesterol management 
and clinical practice [20, 21]. Variations in treatment intensity, i.e. how closely the patients are 
titrated with drugs to attain guideline recommended goals, may also influence LLD sales. 
Previous studies have found low rates of attainment of the total cholesterol (TC) treatment goal 
among LLD users, but regional variations within a country have barely been explored [20-22]. 
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In this epidemiological study we investigated whether differences in morbidity or in cholesterol 
management could explain variation in LLD sales between two counties. Hence, the following 
factors were studied in Hedmark and Oppland:  
 Treatment eligibility: prevalence of cardiovascular morbidity, including coronary heart 
disease (CHD) or diabetes; and cardiovascular risk score among participants in the primary 
prevention subgroup (no CHD or diabetes). 
 Treatment frequency: LLD use in the primary and secondary prevention subgroups. 
 Treatment intensity: achievement of TC  5.0 mmol/l among LLD users.  
Methods 
Study population 
In 2000–2001 the Norwegian Institute of Public Health performed the OPPHED Health Study 
in the two neighbouring counties Hedmark and Oppland [23]. All individuals aged 40, 45, 60 
and 75 years of age were invited, and numbered 8754 from Hedmark and 8592 from Oppland. 
A total of 10 598 (61%) of these individuals attended the screening, with similar attendance 
rates within each age- and gender strata. 
The screening included self-administered questionnaires [24], blood pressure measurements, 
and analysis of non-fasting serum total cholesterol (TC). Non-fasting TC was analysed by an 
enzymatic method at the Department of Clinical Chemistry, Ullevål University Hospital, Oslo 
(Hitachi 917 auto-analyzer, Roche Diagnostic, Switzerland). The questionnaire included 
questions on smoking status, family history of CVD and history of diabetes, myocardial 
infarction (MI), angina pectoris and stroke. Individuals who cited stroke as the only 
cardiovascular disease (1.3% in Hedmark, 1.8% in Oppland) were excluded from the analyses 
because of the inability to classify according to stroke subtype [25]. The questionnaire included 
a question with predefined answering categories (yes/previously/no) on the use of LLDs, 
phrased as in previous studies [26]. Participants answering „yes‟ on current use of LLDs were 
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defined as users in the analyses. The response rate to questions on health status and drug use 
included in these analyses was almost 100% (92–99 %). In total, 10 205 of the 10 598 
attendants were included. 
LLD treatment eligibility 
The National Cholesterol Guidelines at the time of screening recommended dietary intervention 
followed by LLD therapy for secondary prevention in those with established CHD and/or 
diabetes, and for primary prevention in individuals with a high risk of CHD (Framingham 10-
year CHD risk ≥ 20%)[14]. The population eligible for LLD use was stratified into two 
subgroups: 
 Secondary prevention subgroup: participants with self-reported CHD (angina pectoris or 
MI) and/or diabetes.  
 Primary prevention subgroup: participants reporting no established CHD or diabetes.  
To estimate cardiovascular risk level among participants in the primary prevention subgroup, 
two different risk models were used. First, the estimated 10-year incidence of CHD was 
calculated by the Framingham risk model [27]. Second, an MI risk score model, developed in 
the 1970ies from Norwegian epidemiological data, was used. This model includes 
(multiplicative) factor values for cigarette consumption, TC concentration, systolic blood 
pressure, family history of CHD, and gender, totalling the individual‟s risk score[28, 29]. To 
exclude the effect of LLD use, the risk scores were calculated for non-users of LLDs only. 
LLD treatment frequency 
The proportions of LLD use within primary and secondary prevention subgroups in the two 
counties were compared. 
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LLD treatment intensity 
Treatment intensity was compared in terms of achievement of the TC treatment goal among 
LLD users. This TC treatment goal was defined according to prevailing national 
recommendations at the time of screening: TC  5.0 mmol/l [14]. 
Statistical methods 
SPSS 10.0 for Windows was used. Categorical variables were compared using the 
2
 test. 
Continuous variables were compared using t-tests for variables with a normal distribution or 
non-parametric Mann–Whitney tests for variables with a skewed distribution. A p value < 0.05 
was considered statistically significant. 
Ethics 
Approval was granted from the National Data Inspectorate and the Regional Committee for 
Medical Research Ethics.  
Results 
LLD treatment eligibility 
No inter-county differences were found in the prevalence of CHD or diabetes (Table 1). The 
mean TC concentration among non-users of LLD showed similar patterns in the primary 
prevention subgroup in both counties (Table 2). In the primary prevention subgroup, the 
estimated 10-year incidence of CHD (Framingham risk model) and the Norwegian MI score  
among  non-users of LLDs were almost the same in both counties (Table 2). Lack of 
differences in TC concentrations, MI risk score levels or prevalence of CHD and diabetes 
should imply similar proportions of the population eligible for LLD treatment. 
In the primary prevention subgroup, among men in particular, a large part of those 
reporting not to be on LLD therapy had a Framingham risk score above the limit set by 
guidelines (Table 2). 
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LLD treatment frequency 
The prevalence of LLD use among men in the primary prevention subgroup was higher in 
Hedmark than in Oppland (Table 3). The same tendency was seen among women. By contrast, 
there were no inter-county differences in LLD use in the secondary prevention subgroup (Table 
3). 
LLD treatment intensity 
In both sexes, a higher proportion of the LLD users in the primary prevention subgroup 
achieved the TC treatment goal in Hedmark than in Oppland (p < 0.05) (Table 4). The same 
tendency was seen in the secondary prevention subgroup, but the inter-county differences were 
not significant.  
Discussion 
Despite equal proportions of population eligible for LLD therapy, more people received LLD 
therapy for primary prevention in the high-consumption county Hedmark. In addition, the LLD 
users in the primary prevention subgroup seemed to be treated more intensively, in terms of a 
higher attainment of TC treatment goals in Hedmark. As the main part of the population 
belongs to the primary prevention subgroup, even a small percentage inter-county difference in 
LLD use in this subgroup will make up a large number of LLD users, with a corresponding 
effect on total LLD sales.  
 
Wholesale statistics may have several limitations. For example, drugs sold from wholesalers are 
not necessarily dispensed, and dispensed drugs from the pharmacies may not be used. Sales 
statistics do not distinguish between drugs sold to individual patients and to hospitals, and the 
patients may have their medication dispensed outside their county of residence. However, LLDs 
are sold in such a high amount, that pharmacy stocks would only constitute a minor error in the 
LLD sales. LLDs are reimbursed as chronic drug therapy and mainly dispensed to patients in 
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primary care. In both counties, only about one per cent of the defined daily doses of LLDs are 
sold to hospitals or others than patients with prescriptions (Marit Rønning, NorPD, personal 
communication). Danish drug statistics confirm these figures [30]. The Norwegian Prescription 
Database (NorPD) shows that only three to four per cent of the C10A prescriptions are 
dispensed in another county than the patient‟s home county Hedmark or Oppland (Marit 
Rønning, NorPD, personal communication). Hence, we can assume that regional differences in 
LLD sales reflect true differences in LLD consumption. 
 
Some LLD substances may be used in higher doses than the defined daily doses, and the 
discrepancy between defined daily dose (DDD) and prescribed daily dose (PDD) may vary 
between the LLD substances. However, the sales of LLDs in both counties are dominated by 
statins  (99%) and the types of statin substances prescribed are similar [11]. Atorvastatin and 
simvastatin constituted about 90% of total LLD sales in Hedmark and Oppland in 2000-2001 
(Atorvastatin 39%, and simvastatin 48%) [11]. 
 
A higher percentage of LLD users in Hedmark had TC below treatment target (5 mmol/L). 
Unfortunately, no information was available of the pre-treatment TC concentration, or the 
absolute TC reduction for those under treatment. However, mean TC concentrations were 
similar among the non-users of LLD in the two counties (in this subgroup), which may indicate 
similar mean pre-treatment TC concentrations in the two primary prevention subgroups on a 
whole. We therefore conclude that a higher LLD treatment intensity in Hedmark is a plausible 
contributing factor in explaining differences in LLD sales. The success in achieving the target 
cholesterol level might reflect the use of higher dosages of LLDs or higher compliance of use. 
These questions will be studied with data from the Norwegian Prescription Registry.  
 
At the time of screening, the use of LLDs for primary prevention was reimbursed by The 
Norwegian National Insurance in patients with familiar hypercholesterolaemia and in subjects 
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with a persistent cholesterol at >8 mmol/L after one year of dietary intervention [17]. 
Simultaneously, national clinical guidelines recommended a more up-to-date use of LLDs for 
primary prevention, based on a multiple risk factor evaluation (Framingham 10-year risk scores 
> 20%) [14]. In this situation, the physicians have graded the cardiovascular risk of their 
patients, interpreted existing clinical guidelines and reimbursement regulations and made their 
choices. The regional difference can possibly to some extent be attributed to these ambiguous 
authoritative instructions. Recently (June 1th 2005), updated reimbursement regulations for 
LLDs were launched in Norway, concurrent to clinical guidelines for primary prevention [19]. 
Hopefully, these may reduce unintended regional differences in LLD use for primary 
prevention in the future.  
 
However, already at 60 year of age a third of men reporting no use of LLDs in the primary 
prevention subgroup had a Framingham 10-year risk score above the limit set by current 
national guidelines. Obviously, there was a potential for higher LLD sales in both counties. 
Hence, the debate regarded the estimated impact of European guidelines on risk labelling, 
medicalisation and resource allocation in the future, seems to be highly relevant also in 
discussions of current practice [1-4].  
 
In conclusion, the large and increasing inter-county differences in LLD sales cannot be 
explained by the size of the population eligible for LLD treatment. A lower threshold for LLD 
therapy for primary prevention, and a more intensive LLD therapy with higher attainment of the 
lipid treatment goal, are probable contributing factors to differences in LLD sales between the 
counties. The gap between observed and guideline-recommended LLD use, may reflect that 
adherence to Framingham-based thresholds for intervention have been problematic in clinical 
practice. Norwegian population studies have shown that European SCORE-based guidelines 
classify most adults at high CVD risk, with an “unfavourable” high cholesterol [2, 5, 6]. 
Implementation of these guidelines may lead to a marked increase in the pharmacological 
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treatment, especially in men and among the elderly [5]. Hence, we would expect a continuance 
in regional differences in LLD sales. If guidelines shall fulfill their intention of being an 
effective tool in targeting primary prevention intervention, this would obviously presuppose 
taking into account total resources and follow-up capacity in the primary health care. 
Hopefully, a revision of Norwegian guidelines will end up in feasible intervention thresholds 
for primary prevention with concurrent reimbursement rules, thus avoiding regional 
unintentional variations in LLD use for primary prevention in the future.  
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Figures and tables 
 
Figure 1. Sales of lipid-lowering drugs (ATC-group C10) in DDD/1000 inhabitants/day sold in 
the counties Hedmark and Oppland, and a mean for all counties in Norway in 1999-2003[11] 
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* Norway (mean) includes a 95% confidence interval. 
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Table 1. Proportion of participants in secondary and primary prevention subgroup
a
 in high 
(Hedmark) and low (Oppland) lipid-lowering drug (LLD) consumption by county according to age 
and sex. The OPPHED Health Study 2000-2001. 
 
  Men
b
   Women
b
 
 
Age Prevention  Hedmark Oppland  Hedmark Oppland 
 
(years)  subgroup
a
   (%)   (%)     (%)   (%) 
 
       
 
  N=1350 N=1327  N=1627 N=1583 
 
40+45 Secondary     3.6     2.9       1.7     1.3 
 
 Primary  96.4 97.1   98.3 98.7 
 
       
 
  N=641 N=590  N=641 N=694 
 
60 Secondary  17.2 15.8     8.3     8.6  
 
 Primary  82.8 84.2  91.7 91.4 
 
       
 
  N=450 N=390  N=480 N=432 
 
75 Secondary  34.7 34.4  27.5 26.6 
 
 Primary  65.3 65.6  72.5 73.4 
 
       
 
  N=2441 N=2307  N=2748 N=2709 
 
Total Secondary   12.9 11.5     7.7     7.2  
  
 Primary   87.1 88.5   97.3 97.8 
 
a
Secondary prevention subgroup: participants with coronary heart disease(CHD) and/or diabetes, 
primary prevention subgroup: participants without CHD and diabetes. 
b
All differences are non-significant (p ≥ 0.05). 
                             03.11.10   20 
Table 2. Mean cardiovascular risk factor level among non-users of lipid-lowering drugs (LLDs) in 
the primary prevention subgroup
a
 in high (Hedmark) and low (Oppland) LLD consumption regions 
according to age and sex. The OPPHED Health Study 2000–2001. 
                     Men                 Women 
 
  Hedmark Oppland  Hedmark   Oppland 
 
Age (years)  Risk factors  Mean  (SD)      Mean (SD)    Mean (SD)  Mean (SD) 
 
  N=1226 N=1237  N=1557 N=1509 
 
40+45 Mean TC    5.7 (1.02)    5.7 (1.00)    5.4 (0.91)   5.4 (0.93) 
 
 Framingham score    7.2 (4.21)    6.9 (4.09)    2.6 (2.28)   2.7 (2.44) 
 
       % score > 20   1.0    1.1   0.1 0.1 
 
 MI score
b
 17.5    15.6*    2.6  2.5 
       
 
  N=446 N=449  N=496 N=545 
 
60 Mean TC     6.0 (0.98)     6.0 (0.92)    6.4 (1.15)   6.4 (0.98) 
 
 Framingham score   17.4 (6.36)   17.6 (6.67)    9.8  (5.24)   9.9 (5.30) 
 
       % score > 20 30.9 33.4  5.2 5.5 
 
 MI score
b
  20.0 19.5   4.3  4.0 
       
 
  N=252 N=227  N=264 N=269 
 
75 Mean TC     5.9 (1.00)        6.0 (1.00)**     6.7 (1.14)     6.8 (1.24) 
 
 Framingham score   26.9 (8.32)  27.8 (8.22)   12.7 (5.54)   12.8 (5.46) 
 
       % score > 20 80.6 81.9  11.0 11.9 
 
 MI score
b
 25.1 23.8    7.8   7.6 
       
 
  N=1924 N=1913  N=2317 N=2323 
 
Total  Mean TC    5.8 (1.01)     5.8 (1.00)    5.8 (1.12)   5.8 (1.11) 
 
 Framingham score  12.2 (9.04)   11.9 (9.10)    5.3 (5.32)   5.5 (5.41) 
 
       % score > 20 18.3 18.3  2.4 2.7 
  MI score
b
  18.8   17.5     3.2   3.0 
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a
Primary prevention subgroup: participants without coronary heart disease (CHD) or diabetes. 
b
Norwegian myocardial infarction (MI) score, median and non- parametric Mann–Whitney test used 
because of skewed distribution.  
TC, total cholesterol. 
*p < 0.01. 
**p < 0.05
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Table 3. The proportion of lipid-lowering drug (LLD) users in secondary and primary prevention
a
 
subgroup in high (Hedmark) and low (Oppland) consumption regions. The OPPHED Health Study 
2000–2001. 
              
 
  Men  Women 
 
Age Prevention  Hedmark   Oppland  Hedmark  Oppland 
 
(years) subgroup
a
       N   (%)          N  (%)        N  (%)        N  (%) 
       
40+45 Secondary      46 (34.8)        37 (54.1)      25 (24.0)       20 (25.0) 
 
 Primary  1295 ( 3.9)    1283 ( 2.7)   1558 ( 1.6)   1549 ( 2.1 ) 
 
 Total 1341 ( 4.9)   1320 ( 4.2)   1613 ( 2.0)   1569 ( 2.4 ) 
 
       
 
60    Secondary  104 (62.5)        89 (66.3)    52 (57.7)     57 (52.6) 
 
 Primary  504 (10.9)      489 ( 6.5 )  * 568 (11.6)    610 ( 9.8 ) 
 
 Total   608 (19.7)    578 (15.7)  620 (15.5)    667 (13.5) 
 
       
 
75 Secondary  145 (50.3)    122 (47.5)  121 (53.7)   103 (48.5) 
 
 Primary     284 (  9.2)      246 ( 6.5)  319 (14.1)   298 ( 8.4 )  
 
 Total  429 (23.1)    368 (20.1)    440 (25.0)   401 (18.7)  
 
       
 
Total Secondary      295 (52.2)     248 (55.2)      198 (51.0)     180 (47.2) 
 
 Primary    2083 ( 6.3)   2018 ( 4.1 ) *   2475 ( 5.6)    2457 ( 4.8) 
  
 Total   2378 (12.0)   2266 ( 9.7 ) *   2673 ( 9.0)    2637 ( 7.7) 
 
a
Secondary prevention subgroup: participants with coronary heart disease (CHD) and/or diabetes, 
primary prevention subgroup: participants without CHD and diabetes. 
*p < 0.05. 
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Table 4. Proportion of LLD users achieving serum cholesterol goal of ≤ 5.0 mmol/L . The OPPHED 
Health Study 2000-2001. 
 
  Men  Women 
 
Age Prevention Hedmark  Oppland  Hedmark  Oppland 
 
(years)  subgroup
a
       N  (%)         N  (%)         N  (%)         N  (%) 
         
 
40+45 Secondary  16 (75.0)  20 (70.0)   6 (83.3)  5 (80.0) 
 
 Primary  50 (40.0)       35 (17.1) ** 26 (38.5)  32 (21.9) 
 
         
 
60 Secondary  64 (68.8)  59 (62.7)  30 (43.3)  30 (66.7) 
 
 Primary  55 (45.5)  32 (34.4)  66 (36.4)       60 (18.3) ** 
 
         
 
75 Secondary  73 (68.5)  58 (65.5)  64 (48.4)  50 (40.0) 
 
 Primary  26 (57.7)      16 (31.3)  44 (34.1)       25 (36.0) 
 
         
 
Total Secondary  153 (69.3)  137 (65.0)  100 (49.0)  85 (51.8) 
 
 Primary      131 (45.8)      83 (26.5) *  136 (36.0)     117 (23.1) ** 
 
 Total 284 (58.5)     220 (50.5)  236 (41.5)     202 (35.2) 
 
a
 Secondary prevention subgroup: subjects with coronary heart disease(CHD) and/or diabetes, 
primary prevention subgroup: subjects without CHD and diabetes. 
*  p-value<0.01 
** p-value<0.05 
 
 
 
 
 
 
 
